Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study

Multiple Sclerosis

Volumn 22, Issue 9, 2016, Pages 1192-1201

  Kovacs, Katalin T ^a   Kalluri, Sudhakar Reddy ^b   Boza Serrano, Antonio ^c   Deierborg, Tomas ^c   Csepany, Tunde ^d   Simo, Magdolna ^e   Rokusz, Laszlo ^f   Miseta, Attila ^g,h   Alcaraz, Nicolas ^a   Czirjak, Laszlo ^a   Berki, Timea ^a   Molnar, Tihamer ^a   Hemmer, Bernhard ^a,i   Illes, Zsolt ^h,j  

^a UNIVERSITY OF PÉCS   (Hungary)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Military Hospital   (Hungary)

^g UNIVERSITY OF PÉCS   (Hungary)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁱ Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^j ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

AQP4; IL 17; IP 10; myelin oligodendrocyte glycoprotein; SLE; Th1; Th17

Indexed keywords

ANTINUCLEAR ANTIBODY; AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NUCLEOSOME ANTIBODY; THYMUS AND ACTIVATION REGULATED CHEMOKINE; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; EOTAXIN; INTERLEUKIN 17; METHOTREXATE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAIN ISCHEMIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; PARAPLEGIA; RELAPSE; REMISSION; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT; B LYMPHOCYTE; BLOOD; CASE REPORT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PRELIMINARY DATA; RECURRENT DISEASE; RETROSPECTIVE STUDY; TH1 CELL; TH17 CELL; TIME FACTOR; TREATMENT OUTCOME; CELL ACTIVATION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LONGITUDINAL STUDY;

ADOLESCENT; ADULT; AQUAPORIN 4; AUTOANTIBODIES; B-LYMPHOCYTES; BIOMARKERS; CHILD; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MIDDLE AGED; NEUROMYELITIS OPTICA; PRELIMINARY DATA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TH1 CELLS; TH17 CELLS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84979515569     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515613165     Document Type: Article

References (35)

1. Jarius S, Wildemann B, Paul F,. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014; 176: 149-164.
2. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-1461.
3. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17: 1019-1032.
4. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235-43.
5. Chanson JB, Alame M, Collongues N, et al. Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol. Epub ahead of print 28 2013. DOI: 10.1155/2013/146219.
6. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Nat Acad Sci USA 2011; 108: 3701-3706.
7. Veszeli N, Füst G, Csuka D, et al. A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Mol Immunol 2014; 57: 200-209.
8. Höftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015; 21: 866-874.
9. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71: 276-283.
10. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflamm 2011; 8: 184-198.
11. Nishiyama S, Ito T, Misu T, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009; 72: 1960-1961.
12. Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 2012; 78: 1601-1607.
13. Mitsdoerffer M, Kuchroo V, Korn T,. I mmunology of neuromyelitis optica: a T cell-B cell collaboration. Ann NY Acad Sci 2013; 1283: 57-1266.
14. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol 2008; 65: 78-83.
15. Nasir S, Kerr DA, Birnbaum J,. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 2009; 66: 1160-1163.
16. Pellkofer HL, Hohlfeld R, Kuempfel T,. Thirty-one episodes of myelitis and optic neuritis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 2010; 67: 779-780.
17. Wandinger KP, Stangel M, Witte T, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 2010; 62: 1198-1200.
18. Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011; 17: 1067-1073.
19. Wingerchuk DM, Weinshenker BG,. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012; 18: 5-10.
20. Banati M, Csecsei P, Koszegi E, et al. Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system. Eur J Neurol 2013; 20: 1492-1495.
21. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
22. Kalluri SR, Illes Z, Srivastava R, et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010; 67: 1201-1208.
23. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66: 833-842.
24. Jarius S, Franciotta D, Bergamaschi R, et al. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med 2010; 48: 659-663.
25. Bradl M, Lassmann H,. Experimental models of neuromyelitis optica. Brain Pathol 2014; 24: 74-82.
26. Nelson PA, Khodadoust M, Prodhomme T, et al. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One 2010; 5: e15050.
27. Kalluri SR, Rothhammer V, Staszewski O, et al. Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One 2011; 6: e16083.
28. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012; 72: 53-64.
29. Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988-1002.
30. Wang HH, Dai YQ, Qiu W, et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011; 18: 1313-1317.
31. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010; 16: 1443-1452.
32. Narikawa K, Misu T, Fujihara K, et al. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004; 149: 182-186.
33. Zhang H, Verkman AS,. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest 2013; 123: 2306-2316.
34. Michael BD, Elsone L, Griffiths MJ, et al. Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms-a pilot study. Cytokine 2013; 64: 90-96.
35. de Jager W1, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009; 10: 52.